The system, produced by AIMEDICS, monitors for sleep time hypoglycaemic (low blood sugar) episodes in people with insulin dependent diabetes. If changes occur, the HypoMon triggers an alarm, alerting the user and the caregiver.
AIMEDICS Chairman, Mr Martin Greenberg, is very pleased that AIMEDICS has been recognised on the world stage. “HypoMon is a non-invasive monitor and alarm system and our international award is acknowledgement of our significant, ongoing and relevant investment into the HypoMon technology.”
The HypoMon is suitable for people aged 10 to 25 years of age with further clinical studies planned to expand the age range. The HypoMon is convenient and can be used from home, offering the user a “safer nights sleep for young people with Type 1 Diabetes”. The system is also flexible. The parent of a 10-year-old person with Type 1 diabetes will probably use the HypoMon every night where as a teenager might use it when they have exercised during the day and are at higher risk of hypoglycaemia.
HypoMon is scheduled to go on sale in Australia and Europe for the first time later this year.
CEO of AIMEDICS, Victor Skladnev, has found the working environment at ATP conducive to the development of HypoMon. “ATP’s nurturing environment has allowed us to easily keep up to date with Government programs and simplified our engagement and access to advisors.”
AIMEDICS was established in 2001 based on the work and patents of two inventors from the University of Technology Sydney (UTS). Since then, it has been funded through a series of investments and government grants including the Business Innovation Factory, the NSW Government, JDRF (through UTS) and the Australian federal government.
For more information please visit www.hypomon.com